In a groundbreaking discussion, Aino Kalervo, COO of TILT Biotherapeutics Ltd, delves into the transformative potential of #EngineeredViruses in #cancertreatment. Kalervo highlights TILT's pioneering work with an #adenovirus modified to selectively target and destroy #cancercells without harming healthy tissue. This #oncolyticvirus, known as #TIL123, is specifically engineered for intravenous administration, significantly enhancing treatment efficacy and patient comfort. The integration of oncolyticvirus with other #immunotherapies promises to revolutionize cancer treatment. TILT Biotherapeutics presented innovative data at #ASCO2024 ’s annual meeting. For the full article, see #ONCOLife Special Edition https://lnkd.in/dEPMX98b
Health and Pharma
Internet News
New York, New York State 2,218 followers
Health & Pharma is a global news platform on life sciences, biotech, drug discovery, and pharmaceutical industry events
About us
Health and Pharma is a global news platform on life sciences, biotech, drug discovery, and pharmaceutical industry events. We strive to be a trusted news outlet, delivering firsthand reports from reliable channels. Our goal is to collaborate with health science and pharma professionals.
- Website
-
https://healthandpharma.net/
External link for Health and Pharma
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- New York, New York State
- Type
- Privately Held
Locations
-
Primary
New York, New York State 10027, US
Employees at Health and Pharma
Updates
-
#SenoVax Applies for #FDA #IND: Targeting "Zombie Cells" to Destroy #Tumor Barriers and Combat #LungCancer A new Investigational New Drug application has been submitted to the FDA for SenoVax, targeting the treatment of non-small cell #lung #cancer. SenoVax, utilizes dendritic cell technology to enhance the #immune system's response against senescent cells surrounding tumors, potentially offering a significant breakthrough in #cancertreatment. https://lnkd.in/dDpraD7z
-
Pedro Valencia, discusses how #AbbVie’s strategy is focused on replacing #chemotherapy with #targetedtherapies such as #ADCs, which may significantly increase survival and response rates across multiple #cancers. These potentially transformative therapies, particularly ABBV-400 and ABBV-706, have demonstrated potential in improving clinical outcomes in early studies. For the full article, see #ONCOLife Special Edition https://lnkd.in/gu9tW4XW https://lnkd.in/d2tPKTqp
In this exclusive interview with Pedro Valencia, PhD, Vice President, Solid #Tumor Pipeline Strategy & Execution at AbbVie, he highlights their progress with its Antibody-Drug Conjugates (#ADCs) platform for treating #solidtumors, discussing the data presented at #ASCO2024. Valencia details how AbbVie is focusing on developing innovative ADCs targeting diseases like #colorectal #cancer (#CRC) and non-small cell #lungcancer, which despite recent innovations, still need new treatment options as survival rates remain low and patients often run out of options after multiple cycles of treatment. For the full article, see #ONCOLife Special Edition https://lnkd.in/gu9tW4XW
-
The ARANOTE Phase III trial demonstrated that #Nubeqa (#darolutamide), combined with androgen deprivation therapy (ADT), can significantly improve radiological progression-free survival (rPFS) in men with metastatic hormone-sensitive #prostatecancer (mHSPC). The trial's safety data reaffirm darolutamide's established tolerability profile. #prostate #cancer https://lnkd.in/d2y5AzvS
Darolutamide Shows Promise in Phase III ARANOTE Trial for Treating Prostate Cancer
healthandpharma.net
-
Alto Neuroscience has completed enrollment for its Phase 2b trial of #ALTO100, aimed at treating major #depression. This study evaluates the drug's efficacy using a cognitive #biomarker to personalize treatment. Such an approach could revolutionize #psychiatric care by tailoring treatments to individual #neurobiological profiles, potentially increasing efficacy and reducing the trial-and-error commonly associated with #depressiontherapies. The drug previously showed favorable safety and efficacy in a Phase 2a trial... https://lnkd.in/dRVR6bur
ALTO-100 Trial: Using Cognitive Biomarkers to Personalize Depression Treatment
healthandpharma.net
-
Machine Learning Could Detect Disease from Protein Signatures 15 Years Before It Strikes New predictive models using #machinelearning to analyze #protein patterns from UK #Biobank data could predict #diseaserisks, including #Alzheimer's, #diabetes, and heart disease, up to 15 years in advance. This breakthrough has the potential to transform early detection and prevention strategies in #healthcare. Dr. Christopher Foley PhD, one of the principal investigators, cautioned that more work is needed before these findings can be routinely used in clinical settings. "However, our discoveries set strong foundations for the inclusion of new risk prediction signatures to shed a light on possible pathways and mechanisms that underlie diseases" said Dr. Foley. #AI https://lnkd.in/dUTZd6vH
Machine Learning Could Detect Disease from Protein Signatures 15 Years Before It Strikes
healthandpharma.net
-
The NeuroBlate NB3 FullFire 1.6mm Probe is the smallest cooled brain surgery laser probe available on the market. Our CEO, Marty Emerson, sat down with ONCOLife to discuss the innovative advancements and precision of this minimally invasive surgical tool, which are pivotal for pediatric and oncological neurosurgery. Read the full article here: https://bit.ly/ONCOLife Rx Only. https://bit.ly/3pdAg6x
-
The Future of #BrainTumor Treatment with the #NeuroBlate #LaserProbe https://lnkd.in/d6Y8c8yP
Elevating Safety and Efficacy in #Brain #Tumor Treatment with the NB3 Laser Probe The #NeuroBlate NB3FF #LaserProbe is a pioneering device that promises a new trend in treating #braincancer, including #pediatric #tumors. In this exclusive interview for #ONCOLife, Marty Emerson, CEO of Monteris Medical, delves into the innovative advancements of the smallest #brainsurgery #laser #probe to date. Emerson highlights the probe’s precision and minimal invasiveness, which are pivotal in improving outcomes for pediatric and oncological #neurosurgery. By Hüseyin Kandemir For the full article, see #ONCOLife #ASCO2024 Special Edition https://lnkd.in/gu9tW4XW
-
Health and Pharma reposted this
🎙 El Dr. Rafael Rosell, Director Médico y Presidente del Instituto Oncológico Dr. Rosell, ha sido entrevistado por la revista médica ONCOLife, de Health and Pharma. En la entrevista, se destaca el estudio #KROCUS, presentado en la reunión anual de la American Society of Clinical Oncology (ASCO). 🔬 El estudio KROCUS, liderado por el Dr. Rosell, ha demostrado una notable eficacia de un 81-82% en pacientes con cáncer de pulmón de células no pequeñas y mutación KRAS G12C, quienes recibieron una terapia combinada de medicamentos más amigable para los pacientes, sin haber sido sometidos a tratamientos previos. 📄 En el documento adjunto, podéis leer la entrevista completa y conocer más sobre los significativos resultados de este estudio y su relevancia en la lucha contra el cáncer de pulmón. 🔗 Accede a la edición especial completa sobre ASCO 2024 aquí: https://lnkd.in/gu9tW4XW
-
The first patients have been recruited for #VISIONtrial, which evaluates the role of #digitaltwins and #AI in tailoring treatment for #breastcancer. The study focuses on personalizing care and improving outcomes by predicting therapy responses, marking a significant step forward in developing better #cancer treatments. Dr. Irina Babina, CEO of #Concr, emphasized the practical benefits of AI in #healthcare, stating, “While much of the dialogue surrounding AI in healthcare focuses on its potential, we must not overlook the fact that AI tools can - and do - deliver tangible benefits to patients today. VISION is testing a novel individualised care approach designed by clinicians, leveraging latest technology alongside existing diagnostic tests, to facilitate rapid adoption.” https://lnkd.in/dzjxjFUJ
VISION Trial Employs AI and Digital Twins to Tailor Breast Cancer Treatment
healthandpharma.net